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Original ArticleEffect of Tranexamic Acid on Prevention of Hemorrhagic Mass Growth in Patients with
Traumatic Brain InjuryEsmaeil Fakharian, Masoumeh Abedzadeh-kalahroudi, Fatemeh Atoof-BACKGROUND: Intracranial hemorrhage is a common
complication of traumatic brain injury (TBI). The purpose of
this study is evaluation of the effect of tranexamic acid
(TXA) on hemorrhagic mass growth in TBI patients.
- PATIENTS AND METHODS: In this randomized, double-
blind clinical trial, 149 patients with TBI and any kind of
blood on their computed tomography scan enrolled in the
study and were randomly allocated to receive TXA or
placebo. After 24 hours, computed tomography scan was
repeated for assessing the changes in hemorrhage, new
bleeding, and mass effects of blood on brain tissue. The
primary outcome was growth of the hemorrhagic lesion.
Data were analyzed by SPSS software using Fisher exact,
chi-square, and Mann-Whitney U tests, as well as linear
and logistic regression models.
- FINDINGS: The incidence of hemorrhagic lesion growth
was 20.5% in the TXA group and 22.7% in the placebo
group. The difference was not significant (P [ 0.87,
RR [ 0.89). The mean (standard deviation) of hemorrhagic
lesion growth was 9.4 (15.3) in the TXA group and 10.2 (10.1)
in the placebo group without significant difference
(P [ 0.27). The frequency of deaths (2.7% vs. 4%), adverse
outcome at discharge (10.8% vs. 17.3%), and 3 months later
(6.8% vs. 14.7%) in the TXA group were lower than the
placebo, but the difference was not statistically significant.
No side effect was observed with the administration
of TXA.
-CONCLUSION: Administration of a short dose of TXA
does not lead to significant prevention of growth ofKey words
- Intracranial hemorrhage
- Tranexamic acid
- Traumatic brain injury
Abbreviations and Acronyms
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GCS: Glasgow Coma Scale
GOS: Glasgow Outcome Scale
ICH: Intracranial hemorrhage
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e748 www.SCIENCEDIRECT.com WORLD NEposttraumatic hemorrhagic lesion or improvement of clin-
ical outcomes.INTRODUCTIONraumatic brain injury (TBI) is one of the major causes of
death and disability in the world. It is estimated that 1.5Tmillion patients die annually due to TBI.1 The annual
incidence rate of TBI in the United States is between 180 and
250 per 100,000 population,2 and this ﬁgure is calculated
between 15.3 and 144 per 100,000 population in Tehran, Iran.3
TBI is classiﬁed into 3 categories based on the Glasgow Coma
Scale (GCS): severe (10%); moderate (10%); and mild (80%).4
Intracranial hemorrhage (ICH) is a common complication of
TBI, which may progress and worsen after admission to the
hospital.5 About three fourths of patients with TBI have
intracranial hemorrhage,6 which may get larger while admitted
to the hospital in about half of patients.7,8 It is told that this
bleeding is associated with a high risk of coagulopathy, and this
may lead to increase in hemorrhage size, higher mortality, and
disability. Increase in ﬁbrinolysis, which implies high levels of
ﬁbrin degradation products, is a common pattern of coagulopathy
in TBI. Therefore antiﬁbrinolytic agents such as TXA may reduce
ICH due to trauma.5
Several clinical trials have conﬁrmed the efﬁcacy and safety of
TXA.9-11 In CRASH-2, an international study on the effects of TXA,
20,211 cases of trauma in 40 countries received an early injection
of TXA. This resulted in reduced mortality of those who bled or
were at risk of bleeding without any side effects. The researchers
also concluded that TXA is a cost-beneﬁcial drug in low- andTBI: Traumatic brain injury
TXA: Tranexamic acid
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Figure 1. Study flowchart and CONSORT diagram.
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Health Organization’s list of essential medicines.12
TXA administration in patients with aneurysmal subarachnoid
hemorrhage has reduced the chance of rebleeding but increased
brain ischemia probably due to vasospasm or microvascular
thrombosis.13 Because many patients with trauma-related bleeding
also have TBI, there will be apprehension about the risk of brain
ischemia for these patients.5 Another study in nontraumatic
intracerebral hemorrhages showed that TXA is effective in
stabilizing the hematoma.14 Studies about TXA and TBI are
limited. A subgroup of the CRASH-2 study including 270 cases
with TBI had ICH, and their mean hemorrhagic growth was lower
in the TXA in comparison with the placebo group, although the
difference was not statistically signiﬁcant. It was also found that
TXA had no effect on mortality and disability of these patients.5
Yutthakasemsunt et al,11 in a study of 238 patients with severe
and moderate TBI, concluded that the difference between the 2
groups was not signiﬁcant for progressive ICH, mortality, and
unfavorable outcome. Jokar et al15 concluded in their study that
in spite of an increase in bleeding volume in both the TXA and
placebo groups, the increment in the TXA group was
signiﬁcantly lower than the control. In a systematic review of
CRASH-2 and the Yutthakasemsunt study, it was concluded that
TXA signiﬁcantly reduced the progression of ICH and improved
the clinical outcomes of patients. Finally, in this study, the re-
searchers suggested that more studies and evidence were needed
to support the routine use of this drug in TBI patients.16
Therefore due to limited studies about the effect of TXA on
TBI-induced bleeding and the various effects of this drug on the
outcomes of traumatic patients, this study was conducted to
investigate the effect of TXA in prevention of increase in bleeding
volume in TBI patients. If its effect was proven, it could be used as
one of the routine drugs in the trauma emergency ward for
reducing the mortality and morbidity of TBI.
PATIENTS AND METHODS
This is a double-blind, randomized clinical trial on 150 patients
with TBI admitted to Shahid Beheshti University Hospital, Kashan
University of Medical Sciences, Kashan-IR during 2014e2016.
Participants
Patients with isolated TBI or multiple trauma patients, with TBI as
the main problem, who arrived at the hospital within 8 hours of
trauma, aged 15 and older, with nonpenetrating injury and any
kind of traumatic intracranial bleedings (subdural hemorrhage
[SDH], subarachnoid hemorrhage, contusion, intraventricular
hemorrhage, and epidural hematoma) in admission CT scans, no
need for brain surgery during the ﬁrst 8 hours, no coagulation
disorder, serum creatinine <2 mg, and nonpregnancy were
enrolled to the study. Major organ damage requiring surgical
intervention within the ﬁrst 8 hours, receiving any medication that
disturbs homeostasis, those who do not have a secondary CT scan,
and those who missed follow-up were excluded.
Intervention
The patients complying the inclusion criteria were divided
randomly into 2 intervention and control groups on the basis of 4WORLD NEUROSURGERY 109: e748-e753, JANUARY 2018blocks. In the intervention group, intravenous TXA was adminis-
tered with the ﬁrst dose of 1 g in 100 mL of normal saline in 10
minutes and then with a maintenance dose of 1 gram per 1000 mL
of normal saline for 8 hours.5 In the control group, 0.9% normal
saline was used in the same order. Other treatment protocols and
care were routinely done for all patients. Data were recorded in the
checklist by interview and patients’ charts.
In order to blind the study, the syringes containing TXA and
normal saline were coded by 1 of the study contributors and
supplied to the wards. The physicians and nurses who cared for
the patients were unaware of the content of the syringes supplied.
The drug code could be broken in case of a problem or compli-
cation. Within 24e48 hours of intervention, CT scan was repeated
and the size of the hemorrhagic lesion, new bleeding in the scan,www.WORLDNEUROSURGERY.org e749
Table 1. Demographic and Clinical Characteristics of Patients
in 2 Groups
Group TXA Placebo P Value
Age* 42.3  18.3 39.3  18.1 0.31
Gendery
Male 67 (90.5) 66 (88) 0.62
Female 7 (9.5) 9 (12)
Nationalityy
Iranian 70 (94.6) 65 (86.7) 0.1
Non-Iranian 4 (5.4) 10 (13.3)
Trauma causey
Traffic accidents 64 (86.5) 62 (82.7) 0.43
Fall 8 (10.8) 8 (10.7)
Conflict 2 (2.7) 2 (2.7)
Others 0 (0) 3 (4)
GCS at the time of arrival* 12.7  2.83 11.65  3.71 0.14
Systolic blood
pressure (mm Hg*)
118.2  16.3 120  15.6 0.24
Duration of hospital stay* 13.5  14.3 14.5  11.2 0.14
Admission to ICUy
Yes 41 (55.4) 49 (65.3) 0.21
No 33 (44.6) 26 (34.7)
Duration of ICU stay* 11.9  13.7 10.2  9.9 0.46
TXA, tranexamic acid; GCS, Glasgow Coma Scale; ICU, intensive care unit.
*Data are presented as mean and standard deviation.
yData are presented as numbers (%).
Table 2. Comparison of Computed Tomography (CT) Scan
Findings in 2 Groups
Group Variable* TXA Placebo P Value
Skull fracture 29 (39.2) 30 (40) 0.92
Mass pressure effects on
brain tissue in primary CT scan
12 (16.2) 14 (18.7) 0.43
New bleeding 17 (23.33) 14 (18.7) 0.21
Type of hemorrhage
Contusion 36 (48.6) 38 (50.7) 0.80
SDH 22 (29.7) 20 (26.7) 0.67
EDH 16 (21.6) 15 (20) 0.80
SAH 43 (58.1) 35 (46.7) 0.16
TXA, tranexamic acid; SDH, subdural hemorrhage; EDH, epidural hematoma; SAH, sub-
arachnoid hemorrhage.
*Data are presented as number (%).
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examined. To calculate the volume of bleeding, the following
formula was used: multiplying the maximum length of bleeding
and its maximum width by the number of cuts in centimeters
divided by 2.
The primary outcome was assessment of any increase in the
volume of hemorrhagic lesion in comparison with the initial size
and secondary outcomes including the need for brain surgery,
death, functional status based on the Glasgow outcome scale, new
bleeding, and mass effects. At the time of discharge and 3 months
later, functional outcome was assessed by the neurosurgeon based
on the GOS, with a score of 1e5 points on the basis of the
patient’s functional status. A higher score indicates better recov-
ery. Also, patients were evaluated for the complications of TXA
including nausea and vomiting, abdominal pain, and deep vein
thrombosis.
Ethical Consideration
This study was approved at the Ethics Committee of Kashan
University of Medical Sciences. Written consents were obtained
from all patients. This study was also registered on IRCT with the
following number: IRCT201011202854N6.
Statistical Analysis
The Kolmogorov-Smirnov test showed that some of the data do
not have normal distribution. Therefore for statistical analysis
Fisher exact, chi-square, and Mann-Whitney U tests, as well as
linear regression and logistic regression models, were used to
eliminate the possible effects of confounding variables. Data were
analyzed by SPSS software and the signiﬁcance level was consid-
ered 0.05.
RESULTS
Out of 180 patients selected for this study, 20 were excluded due to
the need for surgery (brain or other organs) during the ﬁrst 8
hours, 4 cases were younger than the age of 15 years, 5 did not
receive the second dose of TXA, and the second scan was not
performed for 2. Finally, 149 patients were analyzed in 2 groups
(TXA ¼ 74 and placebo ¼ 75) (Figure 1).
In this study, the patients were matched in 2 groups according
to the variables of age, gender, nationality, cause of trauma, GCS,
systolic blood pressure, duration of hospital stay, admition to ICU
and its duration (Table 1).
There is no statistically signiﬁcant difference in the rate of skull
fracture, mass effects on brain tissue, the occurrence of new
bleeding, and type of hemorrhage between the 2 groups (Table 2).
Table 3 shows a statistically signiﬁcant difference between the 2
groups in terms of changes in volume of hemorrhagic lesion
(P ¼ 0.03).
The prevalence of hemorrhagic lesion growth in the TXA group
was 20.5% versus 22.7% in the placebo group. This difference
between the 2 groups was not signiﬁcant (Table 4). The mean and
standard deviation of the volume of hemorrhagic lesion in the TXA
group was 9.4  15.3 mL and in the placebo group 10.2  10.1 mL.
This difference was not signiﬁcant (P ¼ 0.27). Although the
frequency of deaths and unfavorable outcomes at hospital
discharge and 3-month follow-up in the TXA group is less thane750 www.SCIENCEDIRECT.com WORLD NEUROSURGERY, https://doi.org/10.1016/j.wneu.2017.10.075
Table 3. Comparison of Changes in Volume of Hemorrhagic
Mass in 24 Hours in 2 Groups
Group Change the
Mass Volume* TXA Placebo P Value
Volume reduction 50 (68.5) 38 (50.7) 0.03
Increasing volume 15 (20.5) 17 (22.7)
Without change 8 (11) 20 (26.7)
*Data are presented as number (%).
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cant. The majority (60%) of those who needed surgery had SDH,
and in all deaths (5 cases), SDH was observed with other types of
bleeding.
Linear regression analysis of the effect of age and type of drug
and GCS on the increment of hemorrhagic lesion size showed that
if other variables remain constant, the only factor that has a sig-
niﬁcant effect on the volume of bleeding is the age, so for each
year increase in the age, mean of the hemorrhage decreases by
0.153 (P ¼ 0.013).
Multiple logistic analysis of the effect of the drug on the
outcome of the patients, along with age, GCS, and the increase in
hemorrhagic lesion, showed that although the treatment had no
signiﬁcant effect on the unfavorable outcome, if other variables
remain constant, for each year increase in patient age, the odds for
unfavorable outcome increased by 1.1 times (P ¼ 0.015). Also for
each unit increase in GCS, the odds for unfavorable outcome
decreased by 0.62 (P < 0.001). The effects of increasing the vol-
ume of hemorrhagic lesion in this analysis were not signiﬁcant.DISCUSSION
The study showed that TXA reduced the growth of hemorrhagic
lesion due to TBI without any evidence of increased risk of
thromboembolic events. However, this difference was not statis-
tically signiﬁcant. This ﬁnding is similar to other studies.5,11
However, Zehtabchi et al,16 in their systematic review of the
previously mentioned studies, with pooled analysis showed a
signiﬁcant difference in the growth of hemorrhagic lesion
between the 2 groups and in favor of TXA.Table 4. Comparison of Patients Outcomes in 2 Groups
Group Outcome* TXA
Growth of hemorrhagic mass 15 (20.5)
Need for surgery 8 (10.8)
Death 2 (2.7)
Unfavorable outcome at discharge (GOS) 8 (10.8)
Unfavorable outcome 3 months after discharge (GOS) 5 (6.8)
TXA, tranexamic acid; RR, relative risk; CI, confidence interval; GOS, Glasgow Outcome Scale.
*Data are presented as number (%).
WORLD NEUROSURGERY 109: e748-e753, JANUARY 2018In total, 21.4% (33 people) of the patients had increased volume of
hemorrhagic lesion. This rate has been reported between 7% and
68%.8,17,18 in various studies. In Yutthakasemsunt’s study, this rate
was similar to the current study (22.2%)11 and CRASH-2 study 37%.5
In this study, there was a signiﬁcant difference between the 2
groups in terms of volume changes in the hemorrhagic lesion
within 24 hours (P ¼ 0.03). In the TXA group, the volume
decreased in 68.5% of the cases, increased in 20.5%, and
remained unchanged in 11% of the subjects after 24 hours.
Increased hemorrhagic lesion in the TXA group was seen in 15
out of 74 (20.5%) and in the placebo group in 17 of 75 (22.5%)
patients. The mean and standard deviation of hemorrhagic lesion
volume in the TXA group was 9.4  15.3 mL and in the placebo
group 10.2  10.1 mL. The difference between the 2 groups was
not signiﬁcant. In a study in Thailand, although the increase in
hemorrhagic lesion in the TXA and placebo group was 18% and
27%, respectively, however, the difference was not signiﬁcant.11 In
CRASH-2 study, hemorrhagic lesion growth was 36% in the TXA
and 44% in the placebo group. The mean and standard deviation
of hemorrhagic lesion in the TXA group was 5.9  26.8 mL and
8.8  29.2 mL in the placebo group, and the difference between
the 2 groups was not signiﬁcant.5 Jokar et al,15 in their single blind
study on 80 patients with TBI, showed a signiﬁcant difference in
increasing size of bleeding in the 2 groups. Differences in the
growth of hemorrhagic lesion in various studies may be due to
the differences in timing of CT scanning, difference in
measurement of the volume, and other diagnostic criteria, as
well as the research methodology.
Death rate in the TXA group in this study was 2.7% versus 4% in
the placebo, and the difference between the 2 groups was not
signiﬁcant (P ¼ 1). This ﬁnding is consistent with the CRASH-2
study, where the death rate was 11% in the TXA group and 18%
in the placebo group, without signiﬁcant difference, and it was
found that TXA does not reduce mortality.5 In a Yutthakasemsunt
et al11 study (2013), death rates were 10% in the TXA and 14% in
the placebo group, without difference between the groups. The
lower percentage of death in our study may be due to
differences in the criteria for entry of individuals into the study.
In this study, patients with mild traumatic hemorrhage and any
bleeding volume were enrolled, while Yutthakasemsunt et al.11
studied patients with moderate to severe TBI.
There were no signiﬁcant differences between the 2 treatment
groups in terms of other adverse effects concerning GOS atPlacebo P Value RR (95% CI)
17 (22.7) 0.87 0.89 (0.55e1.74)
12 (16) 0.35 0.67 (0.29e1.55)
3 (4) 1 0.67 (0.12e3.93)
13 (17.3) 0.25 0.62 (0.22e1.46)
11 (14.7) 0.12 0.46 (0.16e1.26)
www.WORLDNEUROSURGERY.org e751
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show any difference in posttraumatic disability of patients, based
on the Oxford Modiﬁed Disability Scale (mOHS) (22% in the TXA
group and 26% in the placebo group).5 Also in the study by
Yutthakasamsunt et al,11 this rate was 18% and 23% for TXA
and placebo, respectively, and there was no difference in
unfavorable outcomes based on GOS between the 2 groups. In
the Zehtabchi et al16 study, there was no improvement in
clinical outcomes in patients with TXA.
In this study, the prevalence of vegetative life in the TXA group
was 4.1% and in the placebo group it was 3.9%. No signiﬁcant
difference was found. The rate in the CRASH-2 study was 22% for
the TXA group and 26% in the placebo, without any signiﬁcant
difference.5 The reason for higher vegetative life in the mentioned
study was in the inclusion of more severe brain trauma patients.
In the TXA group, 10.8% ultimately underwent surgical inter-
vention with craniotomy and hematoma evacuation in all cases,
and in the placebo group, it was 16%. The difference was not
signiﬁcant in the 2 groups. In the CRASH-2 study,5 the rate of
surgery in both groups was 15%. In the Yutthakasamsunt et al11
study this was 3% for the TXA group. However, in the 2
mentioned studies, the difference was not signiﬁcant.
The hemorrhagic mass effects on brain tissue were not signif-
icantly different between the 2 groups, although they were lower in
the TXA group (16.2%) than in the placebo group (18.7%). The
rates were 47% and 60% in CRASH-2 study for TXA and placebo,
respectively, and the difference between the 2 groups was signif-
icant.5 This ﬁnding is much higher than in our study because of
the higher average volume of hemorrhagic mass in the study in
comparison with ours. However, in another study, the rates
were 10% and 8% for TXA and placebo, respectively.11
Within 24 hours of the initiation of treatment, new bleeding
was seen in 23.3% of the patients in the TXA group and 18.7% of
the placebo group, but no signiﬁcant difference was found. The
amounts in the CRASH-2 study5 were 11% and 16% for TXA and
placebo, respectively, although the difference between 2 groups
was not signiﬁcant like ours.
No side effects with TXA were seen in this study. In the study of
Roberts et al,10 the safety of this drug has been reported in a wide
range of patients with traumatic bleeding. In several other studies,
it was also found that TXA was not associated with an increased
risk of thromboembolic events.11,15,16
In linear regression analysis, the patient’s age is the only factor
with a signiﬁcant effect on the volume of bleeding, so bye752 www.SCIENCEDIRECT.com WORLD NEincreasing age, mean hemorrhage volume decreases. This ﬁnding
is in contrast with the concept of increased fragility of vessels by
age and higher incidence of bleeding in the elderly; however, to
our knowledge there is no report or explanation of such a ﬁnding.
It may be due to the younger age of the trauma population in our
country, and the incidence happens in an overall younger age
group who may be physiologically resistant to trauma. Adversely,
those in a lower limit of age may be at a higher risk for their
speciﬁc physiologic state. This ﬁnding may need further consid-
eration and comparison of different age groups with each other in
larger case controlled studies.
Multiple logistic analyses showed that administration of TXA
had no signiﬁcant effect on the unfavorable outcome. Also, the
odds for unfavorable outcome will increase with increasing age
and decrease with increasing GCS. The effect of increase in vol-
ume of hemorrhagic lesion on the patients’ outcome was not
signiﬁcant in this analysis. In the CRASH-2 study, it was found
that after the elimination of the effects of age, GCS, and the type
of treatment (as confounders), the increase in hemorrhagic lesion
size was associated with disability.5 The ﬁnding of unfavorable
outcome with increasing age and lower GCS is a well-known
fact; however, the former is in contrast with the previously
mentioned ﬁnding of decreasing hemorrhage size with increasing
age.
The limitations of this study were the small sample size and
elimination of patients with coagulopathy, which should be
considered in subsequent studies. Its strengths include double-
blind design, randomized block allocation, precise tomographic
data, and 3-month patient follow-up for outcome assessment.
None of the patients were excluded from the follow-up period.
CONCLUSION
Although TXA prevented hemorrhagic mass growth, the difference
was not statistically signiﬁcant. No improvement in clinical out-
comes was observed with the drug. Arrangement of further studies
with larger sample sizes and consideration of the present study
with different doses of TXA is recommended.
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